Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience

Meera Mohan; Melody Renee Becnel; Urvi A. Shah; Huaying Dong; Sravani Gundarlapalli; Timothy Peterson; Jennifer S. Orozco; Sandra Horowitz; Saurabh Chhabra; Binod Dhakal; Sharmilan Thanendrarajan; Sabarinath Venniyil Radhakrishnan; Samer Al Hadidi; Carlyn Tan; Sham Mailankody; Malin Hultcrantz; Neha Korde; Hani Hassoun; Alexander M. Lesokhin; Sheeba K. Thomas; Krina K. Patel; Elisabet E. Manasanch; Donna M. Weber; Aniko Szabo; Gregory P. Kaufman; Hans C. Lee; Maurizio Zangari; Frits van Rhee; Saad Z. Usmani; Anita D'Souza; Robert Z. Orlowski; Carolina Schinke

doi:10.1002/ajh.26580

Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience

Meera Mohan, Melody Renee Becnel, Urvi A. Shah, Huaying Dong, Sravani Gundarlapalli, Timothy Peterson, Jennifer S. Orozco, Sandra Horowitz, Saurabh Chhabra, Binod Dhakal, Sharmilan Thanendrarajan, Sabarinath Venniyil Radhakrishnan, Samer Al Hadidi, Carlyn Tan, Sham Mailankody, Malin Hultcrantz, Neha Korde, Hani Hassoun, Alexander M. Lesokhin, Sheeba K. ThomasKrina K. Patel, Elisabet E. Manasanch, Donna M. Weber, Aniko Szabo, Gregory P. Kaufman, Hans C. Lee, Maurizio Zangari, Frits van Rhee, Saad Z. Usmani, Anita D'Souza, Robert Z. Orlowski, Carolina Schinke

Lymphoma-Myeloma

Research output: Contribution to journal › Letter › peer-review

5 Scopus citations

Original language	English (US)
Pages (from-to)	E276-E280
Journal	American journal of hematology
Volume	97
Issue number	7
DOIs	https://doi.org/10.1002/ajh.26580
State	Published - Jul 2022

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.26580

Cite this

Mohan, M., Becnel, M. R., Shah, U. A., Dong, H., Gundarlapalli, S., Peterson, T., Orozco, J. S., Horowitz, S., Chhabra, S., Dhakal, B., Thanendrarajan, S., Radhakrishnan, S. V., Al Hadidi, S., Tan, C., Mailankody, S., Hultcrantz, M., Korde, N., Hassoun, H., Lesokhin, A. M., ... Schinke, C. (2022). Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience. American journal of hematology, 97(7), E276-E280. https://doi.org/10.1002/ajh.26580

Mohan, M, Becnel, MR, Shah, UA, Dong, H, Gundarlapalli, S, Peterson, T, Orozco, JS, Horowitz, S, Chhabra, S, Dhakal, B, Thanendrarajan, S, Radhakrishnan, SV, Al Hadidi, S, Tan, C, Mailankody, S, Hultcrantz, M, Korde, N, Hassoun, H, Lesokhin, AM, Thomas, SK , Patel, KK, Manasanch, EE, Weber, DM, Szabo, A, Kaufman, GP, Lee, HC, Zangari, M, van Rhee, F, Usmani, SZ, D'Souza, A, Orlowski, RZ & Schinke, C 2022, 'Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience', American journal of hematology, vol. 97, no. 7, pp. E276-E280. https://doi.org/10.1002/ajh.26580

@article{893f3e57cbff4415b1b01e13c72f3185,

title = "Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience",

author = "Meera Mohan and Becnel, {Melody Renee} and Shah, {Urvi A.} and Huaying Dong and Sravani Gundarlapalli and Timothy Peterson and Orozco, {Jennifer S.} and Sandra Horowitz and Saurabh Chhabra and Binod Dhakal and Sharmilan Thanendrarajan and Radhakrishnan, {Sabarinath Venniyil} and {Al Hadidi}, Samer and Carlyn Tan and Sham Mailankody and Malin Hultcrantz and Neha Korde and Hani Hassoun and Lesokhin, {Alexander M.} and Thomas, {Sheeba K.} and Patel, {Krina K.} and Manasanch, {Elisabet E.} and Weber, {Donna M.} and Aniko Szabo and Kaufman, {Gregory P.} and Lee, {Hans C.} and Maurizio Zangari and {van Rhee}, Frits and Usmani, {Saad Z.} and Anita D'Souza and Orlowski, {Robert Z.} and Carolina Schinke",

note = "Funding Information: Urvi A. Shah has received grants and research support from Celgene/Bristol Myers Squibb, Janssen paid to the institution, personal fees from Janssen, and honorariums for continuing medical education activity from MJH Life Sciences, ACCC, MashUpMD, all outside of the submitted work. Malin Hultcrantz reports research funding from GSK, outside the submitted work. Hani Hassoun reports grants from Celgene, Takeda, and Janssen, outside the submitted work. Neha Korde reports research funding through Amgen and participates in advisory board with Medimmune and honorariums for continuing medical education activity from MJH Life Sciences, outside of the submitted work. Alexander M. Lesokhin reports grants from Novartis, during the conduct of the study; grants from Bristol Myers Squibb; personal fees from Trillium Therapeutics; grants, personal fees and nonfinancial support from Pfizer; and grants and personal fees from Janssen, outside the submitted work. Alexander M. Lesokhin also has a patent US20150037346A1 with royalties paid. Sham Mailankody reports research funding from Allogene Therapeutics, Juno/Bristol Myers Squibb, Takeda Oncology, and Janssen Oncology; personal fees from Plexus communication, and Physician Education Resource, MJH Life Sciences outside the submitted work. Carlyn Tan reports other from Janssen Research and Development outside the submitted work. Saad Z. Usmani reports grant support from Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX and Takeda; personal fees from Amgen, BMS, Celgene, EdoPharma, Genentech, Gilead, GSK, Janssen, Oncopeptides, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda and TeneoBio; outside the submitted work. All the other co‐authors have no relevant conflict of interest. Anita D'Souza reports institutional Research Funding: Abbvie, Takeda, Sanofi, Prothena, Caelum, TeneoBio, Janssen, Regeneron; Ad Board: BMS, Imbrium, Pfizer; Consulting: Janssen, Prothena. ",

year = "2022",

month = jul,

doi = "10.1002/ajh.26580",

language = "English (US)",

volume = "97",

pages = "E276--E280",

journal = "American journal of hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "7",

}

TY - JOUR

T1 - Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma

T2 - A multi-institutional experience

AU - Mohan, Meera

AU - Becnel, Melody Renee

AU - Shah, Urvi A.

AU - Dong, Huaying

AU - Gundarlapalli, Sravani

AU - Peterson, Timothy

AU - Orozco, Jennifer S.

AU - Horowitz, Sandra

AU - Chhabra, Saurabh

AU - Dhakal, Binod

AU - Thanendrarajan, Sharmilan

AU - Radhakrishnan, Sabarinath Venniyil

AU - Al Hadidi, Samer

AU - Tan, Carlyn

AU - Mailankody, Sham

AU - Hultcrantz, Malin

AU - Korde, Neha

AU - Hassoun, Hani

AU - Lesokhin, Alexander M.

AU - Thomas, Sheeba K.

AU - Patel, Krina K.

AU - Manasanch, Elisabet E.

AU - Weber, Donna M.

AU - Szabo, Aniko

AU - Kaufman, Gregory P.

AU - Lee, Hans C.

AU - Zangari, Maurizio

AU - van Rhee, Frits

AU - Usmani, Saad Z.

AU - D'Souza, Anita

AU - Orlowski, Robert Z.

AU - Schinke, Carolina

N1 - Funding Information: Urvi A. Shah has received grants and research support from Celgene/Bristol Myers Squibb, Janssen paid to the institution, personal fees from Janssen, and honorariums for continuing medical education activity from MJH Life Sciences, ACCC, MashUpMD, all outside of the submitted work. Malin Hultcrantz reports research funding from GSK, outside the submitted work. Hani Hassoun reports grants from Celgene, Takeda, and Janssen, outside the submitted work. Neha Korde reports research funding through Amgen and participates in advisory board with Medimmune and honorariums for continuing medical education activity from MJH Life Sciences, outside of the submitted work. Alexander M. Lesokhin reports grants from Novartis, during the conduct of the study; grants from Bristol Myers Squibb; personal fees from Trillium Therapeutics; grants, personal fees and nonfinancial support from Pfizer; and grants and personal fees from Janssen, outside the submitted work. Alexander M. Lesokhin also has a patent US20150037346A1 with royalties paid. Sham Mailankody reports research funding from Allogene Therapeutics, Juno/Bristol Myers Squibb, Takeda Oncology, and Janssen Oncology; personal fees from Plexus communication, and Physician Education Resource, MJH Life Sciences outside the submitted work. Carlyn Tan reports other from Janssen Research and Development outside the submitted work. Saad Z. Usmani reports grant support from Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX and Takeda; personal fees from Amgen, BMS, Celgene, EdoPharma, Genentech, Gilead, GSK, Janssen, Oncopeptides, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda and TeneoBio; outside the submitted work. All the other co‐authors have no relevant conflict of interest. Anita D'Souza reports institutional Research Funding: Abbvie, Takeda, Sanofi, Prothena, Caelum, TeneoBio, Janssen, Regeneron; Ad Board: BMS, Imbrium, Pfizer; Consulting: Janssen, Prothena.

PY - 2022/7

Y1 - 2022/7

UR - http://www.scopus.com/inward/record.url?scp=85129190892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85129190892&partnerID=8YFLogxK

U2 - 10.1002/ajh.26580

DO - 10.1002/ajh.26580

M3 - Letter

C2 - 35472167

AN - SCOPUS:85129190892

SN - 0361-8609

VL - 97

SP - E276-E280

JO - American journal of hematology

JF - American journal of hematology

IS - 7

ER -

Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this